Association of the adrenergic alpha 2a receptor - 1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder

Hwa Young Lee, Rhee Hun Kang, Jong Woo Paik, Yoo Jung Jeong, Hun Soo Chang, Sang Woo Han, Min-Soo Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Adrenergic α2a receptors (ADRA2A) are expressed in the central nervous system and peripheral tissues. The primary mechanism of action of mirtazapine is the antagonism of central presynaptic α2 receptors. Mirtazapine is reportedly associated with weight gain. Our objective was to determine whether the ADRA2A - 1291C/G polymorphism is associated with weight gain and treatment response to mirtazapine in patients with major depressive disorder (MDD). Methods: The ADRA2A - 1291C/G polymorphism was analyzed in 314 MDD patients and 162 control subjects. All patients were evaluated using the 21-item Hamilton Depression Rating Scale at the beginning of the study and at 1, 2, 4, and 8 weeks of mirtazapine treatment. Results: No relationship was observed between the ADRA2A - 1291C/G polymorphism and MDD. No significant difference was found between responder and non-responder groups when comparing the ADRA2A genotype distribution with treatment response to mirtazapine. Repeated measures ANOVA with the last observation carry-forward test indicated that after adjusting for baseline body weight, age, and gender, the subjects with the C/C genotype exhibited a greater mean body weight gain than the subjects with the C/G or G/G genotype after 8 weeks of mirtazapine treatment (p = 0.052). Conclusions: The ADRA2A - 1291C/G polymorphism does not appear to be a predictor of treatment response to mirtazapine. This polymorphism was weakly associated with weight change after 8 weeks of mirtazapine treatment. Further investigation is required to determine whether other polymorphisms of this gene influence treatment response and weight change in patients receiving mirtazapine.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalBrain Research
Volume1262
DOIs
Publication statusPublished - 2009 Mar 25

Fingerprint

Adrenergic alpha-2 Receptors
Major Depressive Disorder
Weights and Measures
Weight Gain
Therapeutics
Genotype
Body Weight
Presynaptic Receptors
mirtazapine
Adrenergic Receptors
Analysis of Variance
Central Nervous System
Observation
Depression

Keywords

  • Adrenergic α2a receptor
  • Major depressive disorder
  • Mirtazapine
  • Polymorphism
  • Weight gain

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Association of the adrenergic alpha 2a receptor - 1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. / Lee, Hwa Young; Kang, Rhee Hun; Paik, Jong Woo; Jeong, Yoo Jung; Chang, Hun Soo; Han, Sang Woo; Lee, Min-Soo.

In: Brain Research, Vol. 1262, 25.03.2009, p. 1-6.

Research output: Contribution to journalArticle

Lee, Hwa Young ; Kang, Rhee Hun ; Paik, Jong Woo ; Jeong, Yoo Jung ; Chang, Hun Soo ; Han, Sang Woo ; Lee, Min-Soo. / Association of the adrenergic alpha 2a receptor - 1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. In: Brain Research. 2009 ; Vol. 1262. pp. 1-6.
@article{7eeb63893f4045c1ad3947e41b39dcbc,
title = "Association of the adrenergic alpha 2a receptor - 1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder",
abstract = "Background: Adrenergic α2a receptors (ADRA2A) are expressed in the central nervous system and peripheral tissues. The primary mechanism of action of mirtazapine is the antagonism of central presynaptic α2 receptors. Mirtazapine is reportedly associated with weight gain. Our objective was to determine whether the ADRA2A - 1291C/G polymorphism is associated with weight gain and treatment response to mirtazapine in patients with major depressive disorder (MDD). Methods: The ADRA2A - 1291C/G polymorphism was analyzed in 314 MDD patients and 162 control subjects. All patients were evaluated using the 21-item Hamilton Depression Rating Scale at the beginning of the study and at 1, 2, 4, and 8 weeks of mirtazapine treatment. Results: No relationship was observed between the ADRA2A - 1291C/G polymorphism and MDD. No significant difference was found between responder and non-responder groups when comparing the ADRA2A genotype distribution with treatment response to mirtazapine. Repeated measures ANOVA with the last observation carry-forward test indicated that after adjusting for baseline body weight, age, and gender, the subjects with the C/C genotype exhibited a greater mean body weight gain than the subjects with the C/G or G/G genotype after 8 weeks of mirtazapine treatment (p = 0.052). Conclusions: The ADRA2A - 1291C/G polymorphism does not appear to be a predictor of treatment response to mirtazapine. This polymorphism was weakly associated with weight change after 8 weeks of mirtazapine treatment. Further investigation is required to determine whether other polymorphisms of this gene influence treatment response and weight change in patients receiving mirtazapine.",
keywords = "Adrenergic α2a receptor, Major depressive disorder, Mirtazapine, Polymorphism, Weight gain",
author = "Lee, {Hwa Young} and Kang, {Rhee Hun} and Paik, {Jong Woo} and Jeong, {Yoo Jung} and Chang, {Hun Soo} and Han, {Sang Woo} and Min-Soo Lee",
year = "2009",
month = "3",
day = "25",
doi = "10.1016/j.brainres.2009.01.013",
language = "English",
volume = "1262",
pages = "1--6",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Association of the adrenergic alpha 2a receptor - 1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder

AU - Lee, Hwa Young

AU - Kang, Rhee Hun

AU - Paik, Jong Woo

AU - Jeong, Yoo Jung

AU - Chang, Hun Soo

AU - Han, Sang Woo

AU - Lee, Min-Soo

PY - 2009/3/25

Y1 - 2009/3/25

N2 - Background: Adrenergic α2a receptors (ADRA2A) are expressed in the central nervous system and peripheral tissues. The primary mechanism of action of mirtazapine is the antagonism of central presynaptic α2 receptors. Mirtazapine is reportedly associated with weight gain. Our objective was to determine whether the ADRA2A - 1291C/G polymorphism is associated with weight gain and treatment response to mirtazapine in patients with major depressive disorder (MDD). Methods: The ADRA2A - 1291C/G polymorphism was analyzed in 314 MDD patients and 162 control subjects. All patients were evaluated using the 21-item Hamilton Depression Rating Scale at the beginning of the study and at 1, 2, 4, and 8 weeks of mirtazapine treatment. Results: No relationship was observed between the ADRA2A - 1291C/G polymorphism and MDD. No significant difference was found between responder and non-responder groups when comparing the ADRA2A genotype distribution with treatment response to mirtazapine. Repeated measures ANOVA with the last observation carry-forward test indicated that after adjusting for baseline body weight, age, and gender, the subjects with the C/C genotype exhibited a greater mean body weight gain than the subjects with the C/G or G/G genotype after 8 weeks of mirtazapine treatment (p = 0.052). Conclusions: The ADRA2A - 1291C/G polymorphism does not appear to be a predictor of treatment response to mirtazapine. This polymorphism was weakly associated with weight change after 8 weeks of mirtazapine treatment. Further investigation is required to determine whether other polymorphisms of this gene influence treatment response and weight change in patients receiving mirtazapine.

AB - Background: Adrenergic α2a receptors (ADRA2A) are expressed in the central nervous system and peripheral tissues. The primary mechanism of action of mirtazapine is the antagonism of central presynaptic α2 receptors. Mirtazapine is reportedly associated with weight gain. Our objective was to determine whether the ADRA2A - 1291C/G polymorphism is associated with weight gain and treatment response to mirtazapine in patients with major depressive disorder (MDD). Methods: The ADRA2A - 1291C/G polymorphism was analyzed in 314 MDD patients and 162 control subjects. All patients were evaluated using the 21-item Hamilton Depression Rating Scale at the beginning of the study and at 1, 2, 4, and 8 weeks of mirtazapine treatment. Results: No relationship was observed between the ADRA2A - 1291C/G polymorphism and MDD. No significant difference was found between responder and non-responder groups when comparing the ADRA2A genotype distribution with treatment response to mirtazapine. Repeated measures ANOVA with the last observation carry-forward test indicated that after adjusting for baseline body weight, age, and gender, the subjects with the C/C genotype exhibited a greater mean body weight gain than the subjects with the C/G or G/G genotype after 8 weeks of mirtazapine treatment (p = 0.052). Conclusions: The ADRA2A - 1291C/G polymorphism does not appear to be a predictor of treatment response to mirtazapine. This polymorphism was weakly associated with weight change after 8 weeks of mirtazapine treatment. Further investigation is required to determine whether other polymorphisms of this gene influence treatment response and weight change in patients receiving mirtazapine.

KW - Adrenergic α2a receptor

KW - Major depressive disorder

KW - Mirtazapine

KW - Polymorphism

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=61849083606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849083606&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2009.01.013

DO - 10.1016/j.brainres.2009.01.013

M3 - Article

C2 - 19401164

AN - SCOPUS:61849083606

VL - 1262

SP - 1

EP - 6

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -